AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michael H. Carrel CEO | NASDAQ (NMS) Exchange | 04963C209 CUSIP |
| US Country | 1,300 Employees | - Last Dividend | - Last Split | 5 Aug 2005 IPO Date |
AtriCure, Inc. is a medical device company that specializes in the development, manufacturing, and sales of surgical tools designed for the ablation of cardiac tissue, the exclusion of the left atrial appendage, and the temporary blocking of pain through peripheral nerve ablation. The company operates on a global scale, with a significant presence in the United States, Europe, the Asia-Pacific region, and other international markets. Since its incorporation in 2000, AtriCure has established its headquarters in Mason, Ohio, and has expanded its market reach through a combination of direct sales staff and independent distributors. AtriCure's mission is centered around innovating cardiac care, particularly focusing on solutions to address atrial fibrillation and related conditions.
AtriCure boasts a diverse portfolio of products and services designed to support cardiac surgery and pain management. The company’s offerings include: